Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

DermTech, Inc. DMTK NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Diagnostics & Research • US • USD

SharesGrow Score
44/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$7.50
+7878.7%

DermTech, Inc. (DMTK) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $0.09. It has a SharesGrow Score of 44/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is DMTK = $8 (+7878.7% upside).

Financials: revenue is $15M, +43.1%/yr average growth. Net income is $101M (loss), growing at -50.1%/yr. Net profit margin is -659.6% (negative). Gross margin is 1.8% (+3.4 pp trend).

Balance sheet: total debt is $54M against $57M equity (Debt-to-Equity (D/E) ratio 0.95, moderate). Current ratio is 4.59 (strong liquidity). Debt-to-assets is 44.6%. Total assets: $122M.

Analyst outlook: 3 / 7 analysts rate DMTK as buy (43%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 75/100 (Pass), Moat 15/100 (Fail), Future 52/100 (Partial), Income 10/100 (Fail).

$7.50
▲ 7878.72% Upside
Average Price Target
The 12-month price target for DermTech, Inc. is $7.50.

DMTK SharesGrow Score Overview

52/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 75/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 15/100
Gross margin is + market cap
FUTURE 52/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — DMTK

✓
VALUE Pass
100/100
DMTK trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $8, implying +8410.6% from the current price $0. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
DMTK: +43.1%/yr revenue is, -50.1%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
75/100
Balance sheet DMTK: Debt-to-Equity (D/E) ratio 0.95 (moderate), Current ratio is 4.59 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
15/100
DMTK: Gross margin is 1.8% (+3.4 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 15/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
52/100
Analyst outlook: 3 / 7 analysts rate DMTK as buy (43%). Analyst consensus target is $8 (+8410.6% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
DMTK: Net profit margin is -659.6%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.044-3.8984
Volume3.4M
Avg Volume (30D)1.89M
Market Cap$3.29M
Beta (1Y)2.42
Share Statistics
EPS (TTM)-3.09
Shares Outstanding$32.64M
IPO Date2017-08-10
Employees206
CEOBret Christensen
Financial Highlights & Ratios
Revenue (TTM)$15.3M
Gross Profit$276K
EBITDA$-97.89M
Net Income$-100.89M
Operating Income$-103.74M
Total Cash$55.86M
Total Debt$54.39M
Net Debt$17.65M
Total Assets$121.93M
Price / Earnings (P/E)-0
Price / Sales (P/S)0.21
Analyst Forecast
1Y Price Target$7.50
Target High$7.50
Target Low$7.50
Upside+7,878.7%
Rating ConsensusHold
Analysts Covering7
Buy 43% Hold 57% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS24984K1051

Price Chart

Track all markets on TradingView
DMTK
DermTech, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Medical - Diagnostics & Research
0.04 52WK RANGE 3.90

People Also View

TMDX
TMDX
TransMedics Group, Inc.
$115.68
+2.05%
 FLGT
FLGT
Fulgent Genetics, Inc.
$16.02
+4.71%
 CLPT
CLPT
ClearPoint Neuro, Inc.
$10.38
+3.70%
 CURI
CURI
CuriosityStream Inc.
$3.29
+2.49%
 OM
OM
Outset Medical, Inc.
$4.35
+0.93%
 LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message